Takara Bio to Provide RetroNectin to City of Hope National Medical Center for Clinical Trial of AIDS Gene Therapy.Tokyo, Japan, Dec 16, 2005 - (JCN) - Takara Bio announced on December 15 that it will provide RetroNectin, its proprietary recombinant human fibronectin fragment, to the City of Hope National Medical Center City of Hope is one of 39 NCI-designated Cancer Centers and is located in the city of Duarte, California. City of Hope comprises an ambulatory and in-patient cancer treatment center as well as a biomedical research facility known as the Beckman Research Institute and the City of Hope , a US medical institution specializing in the research of cancer, diabetes and AIDS. The fragment is offered on a paid basis. Using RetroNectin, Dr. Amrita amrita beverage conferring immortality. [Hindu Myth.: Parrinder, 19] See : Immortality Krishnan at the center will conduct a clinical trial of hematopoietic stem cell Hematopoietic stem cell A cell that can develop into any type of specialized blood cell. Mentioned in: Umbilical Cord Blood Banking gene therapy for AIDS. The trial will cover five subjects who have HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection and develop lymphoma. This will be the 39th case of RetroNectin-based gene therapy. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion